Krystal is a biotechnology company dedicated to developing genetic medicines for diseases with significant unmet needs.

In 2023, the company launched its first FDA-approved product, VYJUVEK®, aimed at treating the rare condition Dystrophic Epidermolysis Bullosa (DEB).

VYJUVEK works by providing functional copies of the COL7A1 gene directly to the skin, significantly enhancing healing for DEB patients.

Since its launch, VYJUVEK has generated $50.7 million in net product revenue, with projections indicating sales could reach nearly $300 million in 2024.

Looking ahead, Krystal plans to expand VYJUVEK's availability to Europe and Japan by 2025, currently serving around 1,200 patients in the U.S.

Additionally, the company has developed Ophthalmic B-VEC, a redosable eye drop therapy for ocular complications in DEB, filling critical gaps in treatment options.

Krystal is also advancing KB407, designed to treat cystic fibrosis by delivering functional copies of the CFTR gene directly to the lungs.

Another promising therapy, KB105, targets TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI), with early trials yielding encouraging results.

The company is pursuing KB707, which targets locally advanced and metastatic solid tumors and has received FDA Fast Track Designation for melanoma and lung metastases.

Krystal employs an innovative platform using engineered HSV-1 to deliver therapeutic genes non-invasively, allowing for safer and repeat dosing.

With a market cap nearing $5.2 billion and a remarkable 1800% stock price increase since 2018, Krystal reflects strong investor confidence despite facing competition from companies like Abeona Therapeutics, Vertex, and Merck.

The company operates across four business segments: Dermatology, Respiratory, Oncology, and Ophthalmology, showcasing its diverse portfolio in genetic medicine.